Page last updated: 2024-08-21

arsenic trioxide and Abnormal Karyotype

arsenic trioxide has been researched along with Abnormal Karyotype in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Akasaka, T; Honjo, G; Minoda, S; Nakagawa, M; Ohno, H; Okanoue, Y1
Bergua, J; Boluda, B; Brunet, S; Calasanz, MJ; Cervera, J; Chillón, MC; de laSerna, J; Esteve, J; Fernández, I; Gil, C; González-Campos, J; González-Sanmiguel, JD; Holowiecka, A; Krsnik, I; Labrador, J; Lowenberg, B; Luño, E; Manso, F; Montesinos, P; Moreno, MJ; Pérez-Encinas, M; Ribera, JM; Salamero, O; Sanz, MA; Sobas, M; Tormo, M; Vellenga, E1

Other Studies

2 other study(ies) available for arsenic trioxide and Abnormal Karyotype

ArticleYear
Relapse of acute promyelocytic leukemia in the external auditory canal confirmed by PML/RARA dual-fusion and RARA break-apart fluorescence in situ hybridization.
    Annals of hematology, 2018, Volume: 97, Issue:5

    Topics: Abnormal Karyotype; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; DNA Probes; Ear Canal; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Positron-Emission Tomography; Recurrence; RNA, Messenger; RNA, Neoplasm; Tomography, X-Ray Computed; WT1 Proteins

2018
Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy.
    Leukemia & lymphoma, 2019, Volume: 60, Issue:5

    Topics: Abnormal Karyotype; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Child; Child, Preschool; Chromosome Aberrations; Cytogenetic Analysis; Female; Humans; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; Prognosis; Recurrence; Treatment Outcome; Young Adult

2019